$KPTI
Karyopharm Therapeutics Inc.

2019 Q2 Form 10-Q Financial Statement

#000119312519142973 Filed on May 09, 2019

View on sec.gov

Income Statement

Concept 2019 Q2 2019 Q1 2018 Q4
Revenue $9.493M $155.0K $206.0K
YoY Change -52.27% -98.45% -86.57%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $24.66M $27.10M $18.77M
YoY Change 159.87% 255.64% 205.2%
% of Gross Profit
Research & Development $26.52M $37.97M $38.89M
YoY Change -40.72% -8.1% 11.66%
% of Gross Profit
Depreciation & Amortization $240.0K $250.0K $200.0K
YoY Change 33.33% 47.06% 17.65%
% of Gross Profit
Operating Expenses $51.18M $65.08M $57.66M
YoY Change -5.61% 32.97% 40.68%
Operating Profit -$41.69M -$64.92M -$57.46M
YoY Change 21.42% 66.71% 45.63%
Interest Expense $3.089M $2.998M -$730.0K
YoY Change 375.23% 487.84% -269.77%
% of Operating Profit
Other Income/Expense, Net -$1.721M -$1.229M -$755.0K
YoY Change -360.76% -348.28% -279.33%
Pretax Income -$43.41M -$66.15M -$58.19M
YoY Change 28.91% 72.06% 49.09%
Income Tax $8.000K $10.00K $20.00K
% Of Pretax Income
Net Earnings -$43.42M -$66.16M -$58.21M
YoY Change 29.0% 72.03% 49.1%
Net Earnings / Revenue -457.34% -42684.52% -28257.28%
Basic Earnings Per Share
Diluted Earnings Per Share -$712.6K -$1.087M -$957.4K
COMMON SHARES
Basic Shares Outstanding 60.86M shares 60.86M shares 60.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q2 2019 Q1 2018 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $217.2M $264.4M $328.2M
YoY Change -9.92% 102.0% 124.07%
Cash & Equivalents $75.55M $83.51M $118.0M
Short-Term Investments $141.6M $180.9M $210.2M
Other Short-Term Assets $5.700M $7.000M $6.400M
YoY Change 67.65% 191.67% 220.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $222.8M $271.4M $334.6M
YoY Change -8.9% 103.61% 125.44%
LONG-TERM ASSETS
Property, Plant & Equipment $14.60M $3.617M $3.863M
YoY Change 459.17% 47.39% 76.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00 $0.00 $2.000M
YoY Change -100.0% -100.0% -93.2%
Other Assets $700.0K $700.0K $700.0K
YoY Change 16.67% 133.33% 133.33%
Total Long-Term Assets $15.30M $15.78M $6.580M
YoY Change 27.18% 20.82% -79.35%
TOTAL ASSETS
Total Short-Term Assets $222.8M $271.4M $334.6M
Total Long-Term Assets $15.30M $15.78M $6.580M
Total Assets $238.1M $287.2M $341.2M
YoY Change -7.21% 96.22% 89.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.100M $2.266M $4.332M
YoY Change -71.01% -54.21% -23.53%
Accrued Expenses $29.30M $28.87M $32.49M
YoY Change 27.56% 33.99% 51.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $32.20M $43.86M $46.90M
YoY Change -11.89% -6.15% -5.18%
LONG-TERM LIABILITIES
Long-Term Debt $106.2M $104.4M $102.7M
YoY Change
Other Long-Term Liabilities $17.30M $17.70M $8.500M
YoY Change 162.12% 331.71% 507.14%
Total Long-Term Liabilities $123.5M $122.1M $111.2M
YoY Change 1771.21% 2878.05% 7842.86%
TOTAL LIABILITIES
Total Short-Term Liabilities $32.20M $43.86M $46.90M
Total Long-Term Liabilities $123.5M $122.1M $111.2M
Total Liabilities $155.6M $165.9M $158.0M
YoY Change 260.88% 226.35% 210.88%
SHAREHOLDERS EQUITY
Retained Earnings -$739.9M -$673.7M
YoY Change 38.61% 36.02%
Common Stock $861.2M $857.2M
YoY Change 36.79% 37.14%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $82.47M $121.3M $183.2M
YoY Change
Total Liabilities & Shareholders Equity $238.1M $287.2M $341.2M
YoY Change -7.21% 96.22% 89.24%

Cashflow Statement

Concept 2019 Q2 2019 Q1 2018 Q4
OPERATING ACTIVITIES
Net Income -$43.42M -$66.16M -$58.21M
YoY Change 29.0% 72.03% 49.1%
Depreciation, Depletion And Amortization $240.0K $250.0K $200.0K
YoY Change 33.33% 47.06% 17.65%
Cash From Operating Activities -$48.21M -$66.62M -$48.17M
YoY Change 28.12% 92.26% 769.49%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $49.00K -$1.090M
YoY Change -100.0% -87.17% 2080.0%
Acquisitions
YoY Change
Other Investing Activities $39.80M $32.04M -$102.0M
YoY Change -246.27% 1016.38% 3479.65%
Cash From Investing Activities $39.80M $31.99M -$103.1M
YoY Change -244.2% 1187.88% 3455.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 400.0K 152.0K 167.8M
YoY Change -99.73% -64.57% 631.07%
NET CHANGE
Cash From Operating Activities -48.21M -66.62M -48.17M
Cash From Investing Activities 39.80M 31.99M -103.1M
Cash From Financing Activities 400.0K 152.0K 167.8M
Net Change In Cash -8.010M -34.52M 16.50M
YoY Change -109.78% 8.9% 13.71%
FREE CASH FLOW
Cash From Operating Activities -$48.21M -$66.62M -$48.17M
Capital Expenditures $0.00 $49.00K -$1.090M
Free Cash Flow -$48.21M -$66.67M -$47.08M
YoY Change 29.49% 90.31% 757.56%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
60864445 shares
CY2018Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37499000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
37791000
CY2018Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
292000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
95529000
CY2019Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28868000
CY2019Q1 us-gaap Assets Current
AssetsCurrent
271435000
CY2019Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
225034000
CY2019Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
861215000
CY2019Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2266000
CY2019Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-28000
CY2019Q1 us-gaap Assets
Assets
287214000
CY2019Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
52000
CY2019Q1 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
57124000
CY2019Q1 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
95000
CY2019Q1 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
27 Securities
CY2019Q1 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
180875000
CY2019Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
180918000
CY2019Q1 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
180918000
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
83506000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84220000
CY2019Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2019Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60864445 shares
CY2019Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60864445 shares
CY2019Q1 us-gaap Common Stock Value
CommonStockValue
6000
CY2019Q1 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
104368000
CY2019Q1 us-gaap Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
104650000
CY2019Q1 us-gaap Debt Instrument Convertible Carrying Amount Of The Equity Component
DebtInstrumentConvertibleCarryingAmountOfTheEquityComponent
67850000
CY2019Q1 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
10650000
CY2019Q1 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3245000
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.1101 pure
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3277000
CY2019Q1 us-gaap Liabilities Current
LiabilitiesCurrent
43860000
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P6Y6M
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3447000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3200000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
2259000
CY2019Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6804000
CY2019Q1 us-gaap Liabilities
Liabilities
165930000
CY2019Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
287214000
CY2019Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
22636000
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
15832000
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1375000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14457000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11448000
CY2019Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
701000
CY2019Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3617000
CY2019Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q1 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
714000
CY2019Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7011000
CY2019Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-739909000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
121284000
CY2019Q1 kpti Debt Instrument Estimated Fair Value
DebtInstrumentEstimatedFairValue
107980000
CY2019Q1 kpti Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
264424000
CY2019Q1 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2019Q1 kpti Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
10453000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
69487000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
129464000
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32493000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
334612000
CY2018Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
289060000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
857156000
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4332000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-244000
CY2018Q4 us-gaap Assets
Assets
341192000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
227000
CY2018Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
180627000
CY2018Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
13000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
2001000
CY2018Q4 us-gaap Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear
79 Securities
CY2018Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
212393000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
212179000
CY2018Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
210178000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
118021000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
118737000
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
60829308 shares
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
60829308 shares
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2018Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
102664000
CY2018Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
390000
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
3922000
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
9362000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4532000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
46904000
CY2018Q4 us-gaap Liabilities
Liabilities
158022000
CY2018Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
716000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
341192000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
327000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3863000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6413000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-673748000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
183170000
CY2018Q4 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2019Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
1175000
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
14848000
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11711000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4164000
CY2018Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-160000
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-31696000
CY2018Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38528000
CY2018Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2018Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7621000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38447000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-773000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
295000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
638000
CY2018Q1 us-gaap Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
-430000
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
509000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
495000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
2484000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
429000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34652000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-38459000
CY2018Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
CY2018Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
39000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
48942000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-38942000
CY2018Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108000
CY2018Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
24736000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
382000
CY2018Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
429000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
27602000
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-38459000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41321000
CY2018Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
10000000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4164000
CY2018Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
429000
CY2018Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49602809 shares
CY2019Q1 dei Amendment Flag
AmendmentFlag
false
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3907000
CY2019Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1704000
CY2019Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
522000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-34517000
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65945000
CY2019Q1 us-gaap Debt Instrument Convertible If Converted Value In Excess Of Principal
DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal
0
CY2019Q1 us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5 D
CY2019Q1 us-gaap Debt Instrument Term
DebtInstrumentTerm
P7Y
CY2019Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Type
DocumentType
10-Q
CY2019Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
245000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.09
CY2019Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001503802
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-37000
CY2019Q1 dei Entity Registrant Name
EntityRegistrantName
KARYOPHARM THERAPEUTICS INC.
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2019Q1 dei Document Period End Date
DocumentPeriodEndDate
2019-03-31
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
27103000
CY2019Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-66151000
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
10000
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2016000
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3255000
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
597000
CY2019Q1 us-gaap Interest Expense
InterestExpense
2998000
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1771000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1229000
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31991000
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
152000
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-66623000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-66161000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-41000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
65077000
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
702000000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-64922000
CY2019Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
257000
CY2019Q1 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
27993000
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
49000
CY2019Q1 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
152000
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
60033000
CY2019Q1 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
172500000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-66161000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37974000
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11711000
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
155000
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
3907000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
152000
CY2019Q1 dei Trading Symbol
TradingSymbol
KPTI
CY2019Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
60856295 shares
CY2019Q1 kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
During the five business day period immediately after any five consecutive trading day
CY2019Q1 kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
CY2019Q1 kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98 pure
CY2019Q1 kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-191000
CY2019Q1 kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-263000
CY2019Q1 kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
630000

Files In Submission

Name View Source Status
0001193125-19-142973-index-headers.html Edgar Link pending
0001193125-19-142973-index.html Edgar Link pending
0001193125-19-142973.txt Edgar Link pending
0001193125-19-142973-xbrl.zip Edgar Link pending
d710910d10q.htm Edgar Link pending
d710910dex311.htm Edgar Link pending
d710910dex312.htm Edgar Link pending
d710910dex321.htm Edgar Link pending
d710910dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20190331.xml Edgar Link completed
kpti-20190331.xsd Edgar Link pending
kpti-20190331_cal.xml Edgar Link unprocessable
kpti-20190331_def.xml Edgar Link unprocessable
kpti-20190331_lab.xml Edgar Link unprocessable
kpti-20190331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending